Insight, China's Pharmaceutical Industry

Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

The National Medical Products Administration (NMPA) announced the 106th batch of reference drugs designated for...

Policy / Regulatory

China’s CDE Proposes Framework for Reference Listed Drug Selection Following Marketing Authorization Holder Changes for Foreign-Originator Drugs Manufactured Locally

Fineline Cube Jun 17, 2026

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released two...

Policy / Regulatory

China’s National Health Commission Revises Physician Practice Regulations to Align with Physicians Law and Enhance Multi-Site Practice Framework

Fineline Cube Jun 17, 2026

The National Health Commission (NHC) announced comprehensive revisions to five key regulatory frameworks governing physician...

Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026

Servier Group announced a multi-target research collaboration with the n-Lorem Foundation, a non-profit research organization...

Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026

Shanghai Juncell Therapeutics Co., Ltd. announced it has published its prospectus and filed for listing...

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026

Everest Medicines (HKG: 1952) announced it has struck a licensing agreement with U.S. firm Dimerix...

Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Fineline Cube Jun 16, 2026

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the National Medical Products Administration (NMPA)...

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Fineline Cube Jun 16, 2026

Hinova Pharmaceuticals Inc. (SHA: 688302) announced that final analysis results from the Phase IIa clinical...

Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Fineline Cube Jun 16, 2026

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG:...

Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026

Harbour BioMed (HKG: 2142) announced it will co-establish, together with U.S. biotechnology company BioMap, a...

Company Drug

BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications

Fineline Cube Jun 16, 2026

Bristol-Myers Squibb (BMS, NYSE: BMY) announced that China’s National Medical Products Administration (NMPA) has granted...

Others

Lonza and Antharis Therapeutics Forge Exclusive ADC Partnership – Dual-Payload Platform Targets Gastrointestinal Cancers

Fineline Cube Jun 16, 2026

Lonza Group Ltd. (SWX: LONN) and Antharis Therapeutics announced on June 15, 2026, an exclusive,...

Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026

ZERO Prostate Cancer, the leading prostate cancer organization in the United States, announced on June...

Company Drug

Gilead Sciences Submits sNDA for Once-Weekly Oral Yeztugo PrEP – Potential First Long-Acting Oral HIV Prevention Option

Fineline Cube Jun 16, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has...

Company Deals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Fineline Cube Jun 16, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced a $1+ billion investment in Jacksonville, Florida, to...

Company Deals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Fineline Cube Jun 16, 2026

Lynk Pharmaceuticals Co., Ltd. announced it has published its prospectus and formally applied for listing...

Others

Bayer Secures FDA Approval for Ambelvist – Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose

Fineline Cube Jun 16, 2026

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted...

Company Drug

Shanghai Leadingtac Secures NMPA Approval for LT-010391 – China’s First Clinical-Stage Oral KRAS-G12D Degrader

Fineline Cube Jun 16, 2026

Shanghai Leadingtac Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...

Company Drug

Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis – Expands MEK Inhibitor Franchise

Fineline Cube Jun 16, 2026

Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China’s National Medical Products...

Company Deals

TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals

Fineline Cube Jun 16, 2026

TriApex Laboratories Co., Ltd. announced it has published its prospectus and formally applied for listing...

Insight, China's Pharmaceutical Industry

Johnson & Johnson MedTech and CED Medical Sign Third Strategic Cooperation Agreement to Expand Neurointerventional Partnership Behind Qiangyida Stent

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

China’s CDE Proposes Framework for Reference Listed Drug Selection Following Marketing Authorization Holder Changes for Foreign-Originator Drugs Manufactured Locally

China’s National Health Commission Revises Physician Practice Regulations to Align with Physicians Law and Enhance Multi-Site Practice Framework

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications

Lonza and Antharis Therapeutics Forge Exclusive ADC Partnership – Dual-Payload Platform Targets Gastrointestinal Cancers

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Gilead Sciences Submits sNDA for Once-Weekly Oral Yeztugo PrEP – Potential First Long-Acting Oral HIV Prevention Option

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Bayer Secures FDA Approval for Ambelvist – Novel High-Relaxivity MRI Contrast Agent with Lower Gadolinium Dose

Shanghai Leadingtac Secures NMPA Approval for LT-010391 – China’s First Clinical-Stage Oral KRAS-G12D Degrader

Fosun Pharma Secures NMPA Approval for Fumaining in Pediatric Langerhans Cell Histiocytosis – Expands MEK Inhibitor Franchise

TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals

You Missed

NMPA CDE Issues Draft Guideline to Reduce or Replace Animal Testing for Monoclonal Antibodies, Opening Public Comment

Shanghai RAAS’s SR604 Enters NMPA CDE Rare Disease Encouragement Program for Hemophilia and Factor VII Deficiency Treatment

Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer’s Disease in the United States

Trump Signs Nine New MFN Drug Pricing Agreements, Expanding Pharma Deals to 26 Companies Covering 89% of Branded Market